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My personal perspective about intravascular stents has
been for the most part very positive. From its humble
beginnings in the late ‘70s the stent become a major ther-
apeutic resource and has achieved worldwide application.
However, some disappointments in the last few years
dampened my early unbridled enthusiasm. In my view,
during its third decade of life the stent evolution has been
hampered by unfulfilled goals. I think this is related to a
recent change in attitudes and perceptions by government,
industry, the media, and people in general.
In regard to technological development, starting in the
year 2000 the medical device industry has shown a pervasive
reluctance to invest in new research and development. This
has been a gradual change from the previous 15 years, when
this industry invested boldly in new products, guided only by
their instinct and everybody’s expectation that there should
be a change in the status quo. Reviewing the circumstances
of those days compared to the present, it is apparent that the
differences where global and not just limited to biotechnol-
ogy. The innovative spirit of the ‘80s was evident in the
wondrous technological achievements that arose during this
decade. The launching of the first space shuttle and the
deployment of the first permanently manned space station
left us in awe, although they did not affect us personally.
Conversely, the advent of practical personal computers,
compact discs, and cell phones did. The beginnings of the
Internet were laid out by a burgeoning ARPANET and the
introduction of the transmission control protocol-Internet
protocol (TCP-IP) lead to the World Wide Web. In medicine
and biology the development of PCR (polymerase chain
reaction) made possible a great expansion in DNA and gene
research. Closer to our specialty, it was during the ‘80s that
all major innovations in endovascular treatments developed.
Andreas Gruntzig, who had done the first coronary balloon
angioplasties in Zurich in 1977, moved to Atlanta, Georgia,
and started a program of clinical research and teaching with
unprecedented success. Under his leadership and inspiration
the balloon angioplasty catheter got rapidly refined and the
new technique achieved massive acceptance. During those
years laser, rotational, and, later, directional atherectomy
and the rapid exchange balloon catheter appeared, and so did
stents. Unquestionably, a new revolution in vascular therapy
had started then, with lots of new technologies and applica-
tions of these technologies in very innovative ways.
President Ronald Reagan, who reflected on innovation
in his State of the Union Address before the U.S. Congress
in February 1985 [1], said: ‘‘Let us begin by challenging
our conventional wisdom. There are no constraints on the
human mind, no walls around the human spirit, no barriers
to our progress except those we ourselves erect.’’ More
interestingly, his comments on vascular therapy were quite
foretelling of ongoing developments: ‘‘New laser tech-
niques could revolutionize heart bypass surgery … and
hold out new promise for saving human lives.’’
The specialized medical press was quick to bring
attention to the new trends and to prepare the public for the
changes that occurred a few years later. The social impact
was huge, as millions of patients got access to the new
percutaneous techniques and, inevitably, open surgical
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treatments diminished. Endovascular equipment got
increasingly refined and doctors’ skills steadily improved.
The new endovascular treatments changed from being the
exclusive domain of primary referral centers to being
available at smaller, peripheral hospitals. The competition
between device manufacturers became fierce for an
increasingly lucrative stent market opportunity.
Recent Bad News
During the ‘90s the U.S. FDA made an effort to allow
access to market to as many new products as possible.
However, as questions about safety and effectiveness rel-
ative to established treatments arose, randomized clinical
trials became commonplace, with their attendant large
financial cost to the manufacturers. Because vascular
intervention is closely tied to highly regulated endovascu-
lar devices, the endless questions about the safety and
effectiveness of these devices created more restrictions in
the product label recommendations, and this resulted in
new boundaries to restrain interventional practice. Com-
pared to our surgical colleagues, the practice of vascular
intervention is becoming increasingly stifled by highly
defined use regulations. In other words, freedom to practice
is being curtailed.
The cost of bringing a new stent to market was also
burdened by big investments in worldwide intellectual
property protection and legal settlements, as litigation for
infringement of patent rights raged. The cost of clinical
trial evaluation and those associated with intellectual
property protection may have curtailed the ability and
willingness of the large device companies to invest in
research and development of future projects. The typical 6-
to 8-year time period to develop and bring a completely
new product to patients got substantially shortened as
companies shied away from new approaches to treat vas-
cular disease and embarked on refining already established
endovascular treatments. Invariably short-term projects
with little innovation but a reasonable chance of succeed-
ing replaced long-term projects carrying a higher risk of
failure and cost but also having a chance of becoming
disruptive technology. The result is evident at recent vas-
cular meetings, where the presentation of new technologies
and methods has given up center stage to late-breaking
clinical trials.
Puzzling to me is the new trend of the specialized press
to punish the stent, the stent industry, and interventional
doctors. This is a change from the early days when the
media trumpeted new therapeutic modalities with enthu-
siasm and optimism.
I was never an advocate of drug-eluting stents (DESs),
as I was always concerned with incomplete healing and the
potential for delayed thrombosis. However, I definitely
welcome their beneficial impact in treating patients with
disease that was not previously the realm of the bare metal
stent (BMS). As in so many areas of medicine, we are
ready to accept new risks if the benefit is substantial. The
early trials [2] and recent analysis of comparative trials of
the DES and BMS [3] show similar survival rates for
patients treated with either device but a definitely increased
freedom from coronary revascularization with the DES.
DES thrombosis, albeit delayed in time, is slightly
increased compared to BMS thrombosis. Nonetheless, at
1.5% stent thrombosis, the balance of risk to benefit is
unquestionably positive compared to the benefit afforded.
Furthermore, a recent publication comparing percutaneous
intervention and medical therapy in patients with stable
coronary disease [4] has brought the message that perhaps
too many angioplasties and stent placements are currently
performed in patients with stable coronary artery disease
[5].
All the recent negative news about angioplasty and
stents has created an atmosphere of skepticism among
people who have not been appropriately reminded of the
benefits achieved thus far compared with, let us say, 30
years ago. Thus, it is the obligation of the medical com-
munity to educate the public to avoid damaging
misconceptions in the public opinion. The notion that
angioplasty devices are dangerous and that conservative
treatment is just as effective as aggressive interventional
therapy may cause many symptomatic patients not to seek
prompt medical attention when they need it.
Tracing Back the Development of Stent Technology
Vascular stent evolution has gone, in my opinion, through
three main phases. The first and perhaps the most signifi-
cant is the mechanical phase. During this phase, the need to
achieve flexibility and a low profile for ease of use was the
first motivation to evolve and develop [6–10]. Later, rec-
ognition of the injury effect to the arterial wall produced by
stent deployment [11] led to design changes aimed at
decreasing the ‘‘footprint’’ of the stent struts by making
more elaborate cell designs [12]. The appearance of scores
of new stent designs covered just about all iterations in this
respect [13], practically exhausting further development of
the mechanical phase.
The second phase began with an interest in the effect the
stent materials could have on blood and the arterial wall,
independent of the stent design. This phase led to explo-
ration of alternative metals and alloys as well as surface
texture modifications and surface coatings able to influence
thrombogenicity and cell coverage [14–23]. Unfortunately,
this phase did not progress too far because of the advent of
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the third phase, that of the DES [24]. The DES introduced
profound changes in the healing mechanism of the stent,
almost completely suppressing neointimal formation. This
implicated that the late luminal loss became negligible and
the prevention of repeat revascularization was significantly
improved compared to that with the BMS. Interestingly the
designation BMS, adopted for comparative purposes with
the DES, relegated all non-drug-eluting stents to a unified
and rather pedestrian category, reflecting the general feel-
ing that a BMS is just a stent that has no special properties.
The appearance of the DES almost eliminated interest in
stent materials research and focused all new development
on the quest for new drugs and/or drug release mecha-
nisms. Part of this new trend is due to economic incentive
and part to an attempt to harness the powerful and poten-
tially dangerous effects of the DES.
From the perspective of an interventional radiologist,
the almost-obsessive pursuit of treating vascular disease
with DESs seems rather futile. To anybody who has
examined the histological reaction to stents in vessels of
various sizes, it is apparent that the larger the vessel, the
less restenosis becomes an issue. In fact, in large vessels
such as the thoracic aorta, the lack of healing seen many
months after implantation may represent a problem. Poor
tissue incorporation seems to affect all large vascular
devices such as endovascular bypass, septal occluders,
atrial appendage occluders, and transluminal valves, caus-
ing leaks and dislodgement. In fact, lack of tissue
incorporation and its attendant thrombogenic effects
doomed the mechanical heart and ventricular assist devices
to a thwarted evolution [25].
It seems to me that the premature demise of the interest
in stent material biocompatibility caused by the DES
constitutes the loss of an opportunity to have unraveled
more than one mystery. Had we found a truly biocompat-
ible stent surface, we should have solved the issue of poor
tissue incorporation of large devices and perhaps even
given the mechanical heart another chance.
Nanotechnology: A Way of the Future?
Who knows? However, nanotechnology has made amazing
changes in our lives by allowing the development of
incredibly smart, small, and inexpensive electronic devices.
It seems to have tremendous potential in the pharmaceu-
tical industry, and this is quite logical [26]. The reason to
look into nanotechnology is practical and compelling. How
can we effect a profound biological change without
addressing it at the molecular level? A coronary stent may
weigh a few milligrams but the features on its surface such
as crystals and boundary areas can be larger than cells.
Studies with surface sensitive equipment such as XPS and
TOF-SIMS demonstrate enough chemical heterogeneities
throughout the surface of commercial stents to assure that
proteins dispersed in blood would not have equal interac-
tion from point to point on the device surface [27]. The
same applies to cells interacting with ligands of such
adsorbed proteins [28, 29]. Yet we seem to be interested
only in what happens at the microscopic level, without
paying attention to the fact that biological phenomena are
based on events starting at dimensions two to three orders
of magnitude smaller than cells. The earliest interaction at
time zero during stent placement is with water and elec-
trolytes, followed in seconds to minutes by protein
adsorption, ligand exposure, and cell interaction. Until we
control what happens at the atomic level we will not have a
chance to uniformly affect molecular interaction and, even
less, cell interaction. Controlling a surface at the atomic
level means that we control feature size and its homoge-
neous distribution throughout the surface. Once we identify
a feature with a desirable property, such as affinity for a
certain target molecule or lack thereof for an undesirable
molecule, we must assure that it is homogeneously dis-
tributed throughout the device surface. This should assure a
uniform and predictable biological response. Today vas-
cular implantable devices are of ‘‘medical quality’’ because
they are free of allergens, carcinogens, pyrogens, and
microrganisms and have a clean, smooth surface to the eye
and to the microscope. However, the biological reaction
they induce is ‘‘chaotic’’ viewed from the perspective of
surface biocompatibility. This means a haphazard and
disorganized reaction with the molecular components of
blood and tissues, potentially leading to unpredictable and
undesirable results. The surface properties of the most
varied implantable materials such as polymers and metals
are surprisingly similar because contaminants on the sur-
face are remarkably alike. This may explain the
disconcerting similitude in tissue reaction to materials
believed to have very different properties.
Just as it happens with nanoelectronics, where the quirky
quantum phenomena trick investigators with unexpected
effects, dealing with nanomanufactured surfaces may bring
unsuspected powerful biological effects, and this would be a
fascinating challenge to face. Unfortunately, nanotechnol-
ogy research is not cheap and requires extensive
collaboration with disciplines far removed from biotech-
nology. The electronics industry invests many billions of
dollars annually in nanotechnology to research products that
will be a practical reality many years from now, and this is
their formula for success. Pharmaceutical industries are also
investing significantly in this area. I would surmise that,
today, the device industry is not investing in any meaningful
way in nanotechnology. This may be a mistake, as I believe
that this may be the most viable way out of the technological
slump we are currently in. I would dare to say that if the
J. C. Palmaz: Bring That Pioneering Spirit Back 1097
123
leaders who showed us the way in the ‘80s were alive today,
they would recommend that we devote major efforts to high
technology as the only alternative for the future.
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